Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 15/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.36 |
| ▸ | IARS1 | P41252 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28004804 | 1.00 | DPP4 (0.40) | DPP4DPP8DPP9FAAHDPP7 | |
| SCHEMBL28074283 | 0.85 | ALDH1A1 (0.39) | DPP4DPP8DPP9FAAH | |
| SCHEMBL12877425 | 0.80 | FAAH (0.40) | FAAH | |
| SCHEMBL12171866 | 0.80 | FAAH (0.40) | FAAH | |
| SCHEMBL7276777 | 0.79 | DPP4 (0.46) | DPP4DPP8DPP9FAAHDPP7 | |
| SCHEMBL4595829 | 0.79 | DPP4 (0.44) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL22952874 | 0.79 | DPP4 (0.46) | DPP4DPP8DPP9FAAHDPP7 | |
| SCHEMBL7276787 | 0.79 | DPP4 (0.46) | DPP4DPP8DPP9FAAHDPP7 | |
| SCHEMBL6628997 | 0.78 | FAAH (0.38) | DPP4DPP9FAAH | |
| SCHEMBL6629003 | 0.78 | FAAH (0.38) | DPP4DPP9FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 309 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055150-A1 | GRAIL-1 PEPTIDE PRODUCTS AND METHODS | UNIV MICHIGAN (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4680108-A1 | PEPTIDE MULTIMER PRODUCTS AND METHODS | The Regents of The University of Michigan (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20250263439-A1 | HETERODIMERIC PEPTIDE REAGENTS AND METHODS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-08-21 | — | — | US | disclosed |
| EP-3660040-B1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2025-06-18 | — | — | EP | disclosed |
| EP-4565333-A2 | GRAIL-1 PEPTIDE PRODUCTS AND METHODS | Regents of the University of Michigan (US) | 2025-06-11 | — | — | EP | disclosed |
| US-12269900-B2 | Inhibitors of β integrin-G protein α subunit binding interactions | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-04-08 | — | — | US | disclosed |
| US-20250073355-A1 | CD44-BINDING PEPTIDE REAGENTS AND METHODS | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-03-06 | — | — | US | disclosed |
| US-20250051416-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2025-02-13 | — | — | US | disclosed |
| WO-2025006976-A2 | MRNA DISPLAY LIBRARIES AND METHODS OF USE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2025-01-02 | — | — | WO | disclosed |
| EP-3666792-B1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-12-18 | — | — | EP | disclosed |
| WO-2011075393-A2 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2011-06-23 | — | — | WO | disclosed |
| EP-2307037-A1 | GLUCAGON ANALOGS EXHIBITING ENHANCED SOLUBILITY AND STABILITY IN PHYSIOLOGICAL PH BUFFERS | Indiana University Research and Technology Corporation (US) | 2011-04-13 | — | — | EP | disclosed |
| EP-2300037-A2 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS | Indiana University Research and Technology Corporation (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-2300035-A2 | GIP-BASED MIXED AGONISTS FOR TREATMENT OF METABOLIC DISORDERS AND OBESITY | Indiana University Research and Technology Corporation (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2010148089-A1 | GIP RECEPTOR-ACTIVE GLUCAGON COMPOUNDS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010111617-A2 | PARATHYROID HORMONE PEPTIDES AND PARATHYROID HORMONE-RELATED PROTEIN PEPTIDES AND METHODS OF USE | VAN ANDEL RESEARCH INSTITUTE (US) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010071807-A1 | AMIDE BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010011439-A2 | GIP-BASED MIXED AGONISTS FOR TREATMENT OF METABOLIC DISORDERS AND OBESITY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2009155258-A2 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009155257-A1 | GLUCAGON ANALOGS EXHIBITING ENHANCED SOLUBILITY AND STABILITY PHYSIOLOGICAL PH BUFFERS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055150-A1 | GRAIL-1 PEPTIDE PRODUCTS AND METHODS | TP53, TP53BP1, DDIT3 | DPP4 4410/4885DPP8 3817/4885DPP9 4307/4885 |
| US-20250263439-A1 | HETERODIMERIC PEPTIDE REAGENTS AND METHODS | ERBB2, EGFR, ERBB3 | DPP4 3631/4885DPP8 2927/4885DPP9 2291/4885 |
| US-20250051416-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | DPP4 262/4885DPP8 221/4885DPP9 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.